Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations

Abstract Alzheimer's disease (AD) staging criteria lack standardized, empirical description. Well‐defined AD staging criteria are an important consideration in protocol design, influencing a more standardized inclusion/exclusion criteria and defining what constitutes meaningful differentiation...

Full description

Bibliographic Details
Published in:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Main Authors:	Ronald C. Petersen, Ana Graf, Chris Brady, Susan De Santi, Hana Florian, Jaren Landen, Mike Pontecorvo, Christopher Randolph, Kaycee M. Sink, Maria C. Carrillo, Christopher J. Weber
Format:	Article
Language:	English
Published:	Wiley 2023-10-01
Subjects:	Alzheimer's disease amyloid biomarkers clinical trials cognition cognitive impairment
Online Access:	https://doi.org/10.1002/trc2.12434

Similar Items

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations: Proceedings from the Alzheimer's Association Research Roundtable (AARR) Fall 2021 meeting
by: Ronald C. Petersen, et al.
Published: (2025-01-01)

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
by: Ronald C. Petersen, et al.
Published: (2025-04-01)

Decision making in clinical trials: Interim analyses, innovative design, and biomarkers
by: Kathleen A. Welsh‐Bohmer, et al.
Published: (2023-10-01)

Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study
by: Jori Tomassen, et al.
Published: (2022-01-01)

Exploring the relationship between melanopsin gene variants, sleep, and markers of brain health
by: Ayeisha Milligan Armstrong, et al.
Published: (2025-01-01)

Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic
by: Ana Laura Vives‐Rodriguez, et al.
Published: (2022-01-01)

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
by: Linda J. Van Eldik, et al.
Published: (2024-10-01)

The Mobile Toolbox for remote, self‐administered cognitive assessment in older adults: associations with in‐clinic cognitive testing and Alzheimer's disease biomarkers
by: Roos J. Jutten, et al.
Published: (2025-07-01)

A Pilot Study on Blood Concentration of β-Amyloid (40 and 42) and Phospho-Tau 181 in Horses
by: Valentina Gazzano, et al.
Published: (2025-06-01)

Amyloid PET ordering practices in a memory disorders clinic
by: Katherine W. Turk, et al.
Published: (2022-01-01)

Alzheimer's disease drug development in an evolving therapeutic landscape
by: Stacie Weninger, et al.
Published: (2024-10-01)

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline
by: Andrew P. Merluzzi, et al.
Published: (2019-01-01)

Complex relationships of socioeconomic status with vascular and Alzheimer’s pathways on cognition
by: Dror Shir, et al.
Published: (2024-01-01)

Editorial: The operationalization of cognitive systems in the comprehension of visual structures
by: Michael Winter, et al.
Published: (2024-10-01)

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
by: Clifford R. Jack, et al.
Published: (2024-10-01)

Rethinking the residual approach: leveraging statistical learning to operationalize cognitive resilience in Alzheimer’s disease
by: Colin Birkenbihl, et al.
Published: (2025-01-01)

The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
by: Christopher J. Weber, et al.
Published: (2021-01-01)

Systematic examination of methodological inconsistency in operationalizing cognitive reserve and its impact on identifying predictors of late-life cognition
by: Kerry A. Howard, et al.
Published: (2023-09-01)

Periodontal disease is associated with cognitive dysfunction in aging dogs: a blinded prospective comparison of visual periodontal and cognitive questionnaire scores
by: Curtis Wells Dewey, et al.
Published: (2021-04-01)

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy
by: Anna Linnéa Svenningsson, et al.
Published: (2022-10-01)

Empowering Educators: Operationalizing Age-Old Learning Principles Using AI
by: Julaine Fowlin, et al.
Published: (2025-03-01)

Disease progression and costs at the 3‐year follow‐up of the GERAS‐US study
by: Julie M. Chandler, et al.
Published: (2023-04-01)

Perspectives on the clinical use of anti‐amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology
by: Gregory A. Jicha, et al.
Published: (2024-07-01)

Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET—A Decade of Post-Authorization Insights
by: Aleksandar Jovalekic, et al.
Published: (2024-12-01)

Computerized cognitive testing to capture cognitive decline in Alzheimer's disease: Longitudinal findings from the ARMADA study
by: Roos J. Jutten, et al.
Published: (2025-01-01)

Benzodiazepines: Uses, Dangers, and Clinical Considerations
by: Amber N. Edinoff, et al.
Published: (2021-11-01)

System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment
by: B. Joy Snider, et al.
Published: (2025-04-01)

Development of a video-simulation instrument for assessing cognition in older adults
by: Edward H. Ip, et al.
Published: (2017-12-01)

Ante-mortem cognitive trajectories associated with Aβ and tau biomarker profiles in older adults with cerebrovascular disease: a longitudinal cohort study
by: Emily Rosenich, et al.
Published: (2025-07-01)

Aβ‐reactive T cell polyfunctionality response as a new biomarker for mild cognitive impairment
by: Yen‐Ling Chiu, et al.
Published: (2025-01-01)

Sleep and Alzheimer’s Disease
by: Dongwoo Kang, et al.
Published: (2015-06-01)

Dissociation of Clinical Outcomes and CSF Proteinopathy Biomarkers in Parkinson’s Disease: Cognitive–Affective Dissociation with Specificity for Tau
by: João Paulo Mota Telles, et al.
Published: (2025-10-01)

Plasma amyloid beta biomarkers predict amyloid positivity and longitudinal clinical progression in mild cognitive impairment
by: Takuya Ataka, et al.
Published: (2024-10-01)

Synaptic markers are associated with cognitive decline after accounting for amyloid burden among an at-risk Alzheimer’s disease cohort
by: Elizabeth M. Planalp, et al.
Published: (2025-06-01)

Comorbidity of cerebral amyloid angiopathy and Alzheimer's disease. Clinical case analysis
by: A. Yu. Emelin, et al.
Published: (2023-12-01)

Brain and cognitive correlates of sleep fragmentation in elderly subjects with and without cognitive deficits
by: Claire André, et al.
Published: (2019-12-01)

Actual memory as a mediator of the amyloid‐subjective cognitive decline relationship
by: Xi Chen, et al.
Published: (2019-12-01)

Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
by: Li-Kai Huang, et al.
Published: (2023-10-01)

The free plasma amyloid Aβ1–42/Aβ1–40 ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma Aβ1–42/Aβ1–40 ratio. The BALTAZAR study
by: S. Schraen-Maschke, et al.
Published: (2024-04-01)

Exploring How Low Oxygen Post Conditioning Improves Stroke-Induced Cognitive Impairment: A Consideration of Amyloid-Beta Loading and Other Mechanisms
by: Zidan Zhao, et al.
Published: (2021-03-01)